Novartis AG ADR Stock
€91.20
Your prediction
Novartis AG ADR Stock
Pros and Cons of Novartis AG ADR in the next few years
Pros
Cons
Performance of Novartis AG ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Novartis AG ADR | -1.300% | 6.207% | 4.525% | -2.532% | 1.316% | 26.575% | 29.032% |
| Roche Holding AG ADR | -1.810% | -0.892% | -3.074% | -22.984% | -13.503% | -20.187% | - |
| Bayer AG ADR | -3.790% | -1.493% | -3.650% | -55.705% | -23.256% | -51.111% | -58.228% |
| GSK plc ADR | 0.000% | 3.243% | -4.020% | 13.018% | 13.690% | -2.051% | -14.422% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financial statements of Novartis (NASDAQ: NVS), a prominent player in the pharmaceutical industry, the general impression suggests that the company maintains a solid financial standing. With substantial total assets, a strong revenue base, and a broad diversification through various investments, Novartis appears to be a robust organization in terms of financial health.
Cash Position: Novartis has maintained a considerable cash position in recent years, end of 2022 standing at $7.52B. A strong liquidity profile allows the company to invest in research and development or pursue mergers and acquisitions to drive future growth.
Increasing Revenue: The total revenue increased from $49.9B in 2020 to $52.9B in 2021 and further up to $58.2B in 2022. This growth suggests that the company is effectively generating business, increasing market share, and expanding its product portfolio.
Comments
News
Why Novartis Stock Topped the Market on Tuesday
Scooting past analyst estimates for its latest quarter gave Novartis (NYSE: NVS) a lift on Tuesday. Investors like what they heard about the global healthcare company's inaugural earnings release
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Image source: The Motley Fool.
Novartis Ag (NYSE: NVS)Q1 2024 Earnings CallApr 23, 2024, 8:00 a.m. ET
Operator
Source Fool.com
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
Great dividend stocks don't always have particularly high yields. Still, it's nice to see a solid income stock that boasts one that's higher than average. And if this company can reward its